Navigation Links
Scientists explain unique activity of TB drug pyrazinamide
Date:8/11/2011

WHAT:Pyrazinamide has been used in combination with other drugs as a first-line treatment for people with tuberculosis (TB) since the 1950s, but exactly how the drug works has not been well understood. Now, researchers have discovered a key reason why the drug effectively shortens the required duration of TB therapy. The finding potentially paves the way for the development of new drugs that can help eliminate TB in an infected individual even more rapidly. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and published online on August 11 in Science Express.

Unlike most first-line TB drugs, pyrazinamide does not directly kill Mycobacterium tuberculosis, the bacterium that causes TB, grown in a test tube; rather, the drug acts only on latent TB bacteria that exist in an acidic environment in the body. From previous studies, the investigators knew that shortly after pyrazinamide enters latent M. tuberculosis in the body, the drug converts to its active form, pyrazinoic acid (POA). But they did not know how POA then killed the bacteria, thereby shortening the normal 9- to 12-month course of therapy by several months.

In this study, the researchers learned that once formed, POA binds to a vital bacterial cell protein, ribosomal protein S1 (RpsA), blocking RpsA from decoding M. tuberculosis DNA to create other proteins that keep the bacteria alive in the body. The investigators note that their results explain the mechanism of this enigmatic TB drug, which could assist researchers attempting to develop improved TB drug treatment regimens.


'/>"/>

Contact: Nalini Padmanabhan
padmanabhannm@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1

Related medicine news :

1. BIDMC scientists receive Challenge Awards from Prostate Cancer Foundation
2. Scientists Take Navel-Gazing to New Level
3. Johns Hopkins scientists map genes for common form of brain cancer
4. Scientists May Have Found Missing Link to Common Brain Cancer
5. Have we met before? Scientists show why the brain has the answer
6. Scientists Warn of New Multidrug-Resistant Salmonella
7. Johns Hopkins scientists begin first-of-its-kind research to create blood platelets from stem cells
8. Scientists show swamp gas protects blood vessels from complications of diabetes
9. Scientists receive funding boost to further research into disease mechanisms of Alzheimer’s
10. Scientists ID Gene Linked to Syndrome Behind Elephant Man Disease
11. Scientists developing new therapy for HER2-positive breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... 2016 , ... The Society for Women’s Health Research (SWHR) announced that its ... role. , “No one in Washington led the way to advance women’s health research ... MD, PhD. “We offer our deep gratitude to Phyllis for her passion and performance ...
(Date:5/23/2016)... , ... May 23, 2016 , ... ... on its Chesterfield, Missouri, campus, Standard Process Inc. awarded $6,000 in ... Siewert and Chloe Tillman. Each student is in her fifth trimester of classes ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hadley ... worldwide for people who are blind or visually impaired, announces the election of ... President Charles E. Young. Hadley’s Board of Trustees retained Morris & Berger, a ...
(Date:5/23/2016)... ... May 23, 2016 , ... Four Circles Recovery Center, a leading treatment ... to announce the launch of its new extended care program, Fifth Circle. Available for ... Four Circles or another primary treatment program, Fifth Circle is designed to foster the ...
(Date:5/23/2016)... ... 23, 2016 , ... Bio-Optronics, Inc. is delighted to announce ... its recent and anticipated growth. , Max Elbaz was appointed as Vice President, ... segments. Max joined the Bio-Optronics team in March. His areas of expertise include ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... 19, 2016 BioLineRx Ltd. (NASDAQ/TASE: ... the treatment of multiple cancer and hematological indications, will ... An abstract titled " Clinical response in relapsed/refractory AML ... by BL-8040, a potent CXCR4 antagonist; results of a ... presentation at the European Hematology Association 21st Congress, to ...
(Date:5/19/2016)... and CAMBRIDGE, Massachusetts , May 19, ... in the development of pharmaceuticals and diagnostics based on the ... a new office in Cambridge, MA ... US. The office is located at Kendall Square, ... industry, well-known as the global hub for transforming scientific insights ...
(Date:5/18/2016)... May 19, 2016 ... Research Report initially provides a basic overview ... and manufacturing technology, post which the report ... in the market. Complete report ... pages providing 8 company profiles and 98 ...
Breaking Medicine Technology: